Concentration of milk secretory immunoglobulin A against Shigella virulence plasmid-associated antigens as a predictor of symptom status in Shigella-infected breast-fed infants.
We conducted a prospective, community-based study of healthy breast-fed Mexican infants to determine the protective effects of anti-Shigella secretory IgA antibodies in milk. Milk samples were collected monthly, and stool culture specimens were obtained weekly and at the time of episodes of diarrhea. Nineteen breast-fed infants were found to have Shigella flexneri, Shigella boydii, or Shigella sonnei in stool samples. Ages of the 10 infants with symptomatic infection and the nine with asymptomatic infection did not differ significantly. Milk samples collected up to 12 weeks before infection were evaluated by enzyme-linked immunosorbent assay for secretory IgA antibodies against lipopolysaccharides of S. flexneri, S. boydii serotype 2, S. sonnei, and virulence plasmid-associated antigens. The geometric mean titers of anti-Shigella antibodies to virulence plasmid-associated antigens in milk received before infection were eightfold higher in infants who remained well than in those in whom diarrhea developed. The significance of milk secretory IgA directed against lipopolysaccharide was less clear. We conclude that human milk protects infants against symptomatic shigella infection when it contains high concentrations of secretory IgA against virulence plasmid-associated antigens.
Hayani
K C
KC
Department of Pediatrics, University of Texas Medical School, Houston 77030.
Guerrero
M L
ML
Morrow
A L
AL
Gomez
H F
HF
Winsor
D K
DK
Ruiz-Palacios
G M
GM
Cleary
T G
TG
D000942:Antigens, Bacterial / Q000276:immunology*; D001942:Breast Feeding; D004405:Dysentery, Bacillary / Q000453:epidemiology / Q000276:immunology* / Q000382:microbiology; D004797:Enzyme-Linked Immunosorbent Assay; D005243:Feces / Q000382:microbiology; D006801:Humans; D007071:Immunoglobulin A, Secretory / Q000032:analysis*; D007223:Infant; D007231:Infant, Newborn; D008800:Mexico / Q000453:epidemiology; D008895:Milk, Human / Q000276:immunology*; D010957:Plasmids / Q000276:immunology*; D011379:Prognosis; D011446:Prospective Studies; D016036:Seroepidemiologic Studies; D012761:Shigella boydii / Q000276:immunology* / Q000302:isolation & purification / Q000472:pathogenicity; D012763:Shigella flexneri / Q000276:immunology* / Q000302:isolation & purification / Q000472:pathogenicity; D012764:Shigella sonnei / Q000276:immunology* / Q000302:isolation & purification / Q000472:pathogenicity; D014505:Urban Population / Q000706:statistics & numerical data; D014774:Virulence / Q000276:immunology
D000942:Antigens, Bacterial; D007071:Immunoglobulin A, Secretory